ELTP News Alert Elite Pharma Inc (ELTP) 0.2260 01/01/2015 15

New Post Public Reply Private Reply Replies (0) Message Board

Jan 1, 2015 at 4:08 PM

Elite Pharma Inc (ELTP) 0.2260 $ELTP

Elite Pharmaceuticals receives second abuse deterrent drug formulation patent in Canada
M2 - Wed Dec 17, 8:09AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) announced on Tuesday that it has received the second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" to expand the scope and reach of its patent estate internationally.

Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
GlobeNewswire - Tue Dec 16, 7:38AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property protection covering the Company's abuse deterrent technology with the issuance of a second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance continues to expand the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
GlobeNewswire - Wed Dec 03, 8:56AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for ELI-201, Elite's twice daily abuse-deterrent oxycodone product which utilizes Elite's proprietary pharmacological abuse-deterrent technology.

Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 19, 4:49PM CST

Elite Pharmaceuticals achieves 8% increase in revenues for Q2 fiscal 2015
M2 - Wed Nov 19, 6:15AM CST
Specialist pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) disclosed on Tuesday that its consolidated revenues was USD1.3m for the second quarter of fiscal year 2015 ended 30 September 2014.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
GlobeNewswire - Tue Nov 18, 5:24PM CST
Revenues increase by 8%

Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, November 19, 2014
GlobeNewswire - Thu Nov 13, 4:02PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that management will host a conference call to provide a quarterly business update on Wednesday, November 19, 2014 at 11:00 AM EST. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals Announces New Management Appointments
GlobeNewswire - Fri Oct 24, 6:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP),a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Kenneth Smith, J.D., M.B.A., as Vice President of Legal, Dr. Jason LePree as Vice President of Scientific Affairs and Dr. Sophy Abraham as Head of Regulatory Affairs.

Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
GlobeNewswire - Tue Sep 09, 6:04AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the ELI-200 product. ELI-200 is an undisclosed abuse deterrent opioid product for pain.

Elite Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Wed Sep 03, 12:47PM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) a specialty pharmaceutical company developing a pipeline of pharmacological abuse deterrent opioids with niche generic products, today announced that Nasrat Hakim, Elite's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16 Annual Healthcare Conference on Tuesday, September 9, 2014 at 2:55 PM Eastern Time. The conference is being held at The New York Palace Hotel in New York City.

OTC Daily Trading News: Evoq Properties, Inc. MedBox, Inc. LabStyle Innovations Corp, MyEcheck, Inc. Elite Pharmaceuticals, Inc.
PR Newswire Europe - Tue Aug 19, 10:11AM CDT
LONDON, August 19, 2014 /PRNewswire/ --

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015
GlobeNewswire - Thu Aug 14, 3:14PM CDT
Revenues Increase by 61%, Product Development on Schedule

Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on August 18, 2014
GlobeNewswire - Wed Aug 13, 6:09AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced today that management will host a conference call to provide a quarterly business update at 11:00 AM ET on Monday, August 18, 2014. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals reports launch of pivotal bioequivalence study of ELI-201 in healthy volunteers to address issues in prescription drug abuse
M2 - Wed Jul 16, 9:08AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) disclosed on Tuesday the dosing of the first volunteer in a pivotal bioequivalence study of ELI-201 utilising its proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201
GlobeNewswire - Tue Jul 15, 10:33AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-201, the Company's twice daily abuse deterrent oxycodone/naltrexone product, utilizing Elite's proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals posts higher consolidated revenues of USD4.6m for fiscal 2014
M2 - Tue Jul 01, 2:53AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTC BB:ELTP) stated on Monday its consolidated revenues of USD4.6m for the fiscal year ended 31 March 2014 (fiscal 2014).

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014
GlobeNewswire - Mon Jun 30, 1:05PM CDT
Revenues Increase by 35%, Product Development Accelerating

Elite Pharmaceuticals, Inc. to Host 2014 Fiscal Year End Conference Call on Tuesday, July 1, 2014
GlobeNewswire - Thu Jun 26, 9:56AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carles Puyol Joins Midea at IFA 2026, Celebrating Unity

Leadership, Innovation, and Soccer Collide in Berlin When you’ve got a Barcelona legend like Carles Puyol gracing an event, it's more than just fanfare. This time around, Puyol made waves at Midea's stand during IFA 2026 in Berlin, signaling a strategic power move for both Midea and FC Barcelona. We're talking about a scene where tech innovation meets world-class...

Amwell Revolutionizes Digital Care Platforms in 2026

Amwell's Bold Move in Virtual Care Funny how in today’s digital age, where everyone is glued to their screens, healthcare can still feel like trying to piece together a jigsaw puzzle with missing pieces. But Amwell seems to have cracked the code, redefining digital care delivery like few others. Just recently, they bagged Frost & Sullivan's 2026 United States Technology...

CHiQ Secures AI Award, Elevates Smart Home Living

CHiQ's Big Win in the AI Game In a world where technology rarely stops spinning, CHiQ has carved its own commendable niche. Snagging the AI Home Ecosystem Brand Award at IFA 2026 in Berlin, the brand's knack for pioneering AI tech isn't just a footnote—it's the whole story. The award—enough to make your competitors green with envy—highlights how far they've come in...

Testing Grounds: Navigating PRN Test Insights

Deciphering the PRN Tester Repetition Today we're staring at what feels like déjà vu—a simple PR test peppered with the classic sentence about a fox and a dog. It's like someone left the 'repeat' function stuck on during a slow day at the office. But hey, let’s dig in. Is there something more behind this repetitive text, or are we grumbling at a wall? Unpacking the...

Delisting Gray Wolf Sparks Heated Hunter Nation Debate

Unraveling the Gray Wolf Controversy What are we looking at here—political maneuvering wrapped in a fur coat? Trump's executive order is making some calls I didn’t see coming. By pushing to delist the gray wolf from the Endangered Species Act (ESA), he's stirring up a mix of joy, outrage, and a boatload of debate about environmental ethics, conservation priorities,...

York Space Systems Faces Class Action Headwinds

York Space Systems: Under Legal Fire You ever hear the one about York Space Systems? Yeah, their ticker YSS is buzzing for all the wrong reasons. Not even a year out from their IPO, and already they're tangled in a class action lawsuit that's got investors with their heads in their hands. ClaimsFiler, a shareholder information outfit, just blasted out a reminder for...

Papa John's Faces Securities Class Action Over Missteps

Papa John's Stock Takes a Nosedive Here's a hot potato for you—Papa John's International, Inc. (NASDAQ: PZZA) just got slapped with a securities class action. This ain't a pie you want a slice of, not after the dough they lost in a day's trading frenzy. On August 6, our friends at Papa John's sent their investors scrambling as their stock tumbled from $29.75 to a stark...

Tuya Smart's AI Innovations Steal the Spotlight at IFA

AI Taking Center Stage at IFA 2026 Amidst the chaos of tech exhibitions, something caught my attention—Tuya Smart's push in making AI a household name. Now, you might wonder why I’m bringing this up. Well, because it's not your typical flashy gadget talk. This is about Tuya parading their latest breakthroughs like a peacock at the world's stage, IFA 2026 in Berlin,...

ToolDance X1 CNC Mill Unveils at IFA 2026

IFA 2026 Reveals a Game Changer: ToolDance X1 Listen up, because ToolDance just threw a curveball into the CNC world with the launch of their X1 Smart Desktop CNC Mill at the IFA 2026 in Berlin. This isn't just another gadget—it's a real player aiming to bring manufacturing muscle right to your desktop. Will Wang, the genius behind ToolDance, wants to democratize CNC...

PITAKA Redefines Tech Style With Berlin Launch Event

Setting the Stage for Innovation Ah, Berlin in September—a city that’s hardly shy of showcasing avant-garde moves. And this time, we’re not talking about some cryptic art installation or underground techno rave. Nope, it's PITAKA making waves, transforming an edgy display at The Feuerle Collection. You see, on September 5, they unveiled their 'Wind Over Wheat'...